Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Piccart, Martine; Procter, Marion; Leyland‐Jones, Brian; Goldhirsch, Aron; Untch, Michael; Smith, Ian; Gianni, Luca; Baselga, José; H. Bell, Richard; Jackisch, Christian; Cameron, David; Dowsett, Mitch; H. Barrios, Carlos; Steger, Günther; Huang, Chiun‐Sheng; Andersson, Michael; Inbar, Moshe; Lichinitser, Mikhail; Láng, István; Nitz, Ulrike; Iwata, Hiroji; Thomssen, Christoph; Lohrisch, Caroline; Suter, Thomas; Rüschoff, Josef; Sütö, Tamás; Greatorex, Victoria; Ward, Carol; Straehle, Carolyn; McFadden, Eleanor; Dolci, Mirko; D. Gelber, Richard

doi:10.1056/nejmoa052306

Public

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Published in New England Journal of Medicine • Oct 20, 2005

Authors:

Martine Piccart

Marion Procter

Brian Leyland‐Jones

Abstract

BACKGROUND: Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy and safety after excision of early-stage breast cancer and completion of chemotherapy. METHODS: This international, multicent...

Subject

Trastuzumab

Medicine

Breast cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!